DZ Bank AG Reiterates “Buy” Rating for Fresenius SE & Co. KGaA (FRE)

Fresenius SE & Co. KGaA (FRA:FRE)‘s stock had its “buy” rating reiterated by equities research analysts at DZ Bank AG in a report released on Monday.

Several other equities analysts have also recently commented on the company. Commerzbank Ag set a €85.00 ($98.84) target price on Fresenius SE & Co. KGaA and gave the stock a “buy” rating in a research report on Monday, November 6th. S&P Global set a €85.00 ($98.84) price objective on Fresenius SE & Co. KGaA and gave the stock a “buy” rating in a report on Monday, November 6th. Bank of America Corporation set a €75.00 ($87.21) price objective on Fresenius SE & Co. KGaA and gave the stock a “neutral” rating in a report on Monday, November 6th. Goldman Sachs Group, Inc. (The) set a €78.00 ($90.70) price objective on Fresenius SE & Co. KGaA and gave the stock a “neutral” rating in a report on Monday, November 6th. Finally, Oddo Bhf set a €82.00 ($95.35) price objective on Fresenius SE & Co. KGaA and gave the stock a “buy” rating in a report on Friday, November 3rd. Six analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. Fresenius SE & Co. KGaA has a consensus rating of “Buy” and an average price target of €81.51 ($94.78).

Shares of Fresenius SE & Co. KGaA (FRA FRE) opened at €66.82 ($77.70) on Monday. Fresenius SE & Co. KGaA has a fifty-two week low of €65.00 ($75.58) and a fifty-two week high of €80.00 ($93.02).

TRADEMARK VIOLATION NOTICE: This piece of content was posted by Markets Daily and is the property of of Markets Daily. If you are viewing this piece of content on another website, it was illegally copied and republished in violation of international copyright legislation. The correct version of this piece of content can be accessed at https://www.themarketsdaily.com/2017/11/15/dz-bank-ag-reiterates-buy-rating-for-fresenius-se-co-kgaa-fre.html.

Fresenius SE & Co. KGaA Company Profile

Fresenius SE & Co KGaA, a health care group, provides products and services for dialysis, hospitals, and outpatient medical care worldwide. The company operates through Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed segments. The Fresenius Medical Care segment offers products for patients with chronic kidney failure.

Analyst Recommendations for Fresenius SE & Co. KGaA (FRA:FRE)

Receive News & Ratings for Fresenius SE & Co. KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius SE & Co. KGaA and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply